You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • LB2102
  • (no location specified)
Jan 10, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

Not yet recruiting
  • SLE (Systemic Lupus)
  • CAR T-cell therapy
  • Bangkok, Please Select, Thailand
    King Chulalongkorn Memorial Hospital
Nov 23, 2023

Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)

Recruiting
  • Colorectal Cancer
  • +6 more
  • CEA-targeted CAR-T cells
  • Hangzhou, Zhejiang, China
  • +1 more
Sep 18, 2023

Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)

Not yet recruiting
  • Gastric Cancer
  • +3 more
  • LB1908
  • (no location specified)
Sep 9, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous humanized anti-CD22 chimeric antigen receptor T cells
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector

Not yet recruiting
  • Lymphoid Leukemia
  • Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
  • Treg CD34+ HSPC (Orca-T)
  • Palo Alto, California
    Stanford Cancer Center
Aug 17, 2022

Brain and Nervous System Trial in Palo Alto (B7-H3CART)

Recruiting
  • Brain and Nervous System
  • Palo Alto, California
    Stanford Cancer Institute
Jul 22, 2022

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Myasthenia Gravis Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Myasthenia Gravis
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Neuromyelitis Optica Trial in Hangzhou (CD19 CAR-T cells injection)

Recruiting
  • Neuromyelitis Optica
  • CD19 CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igß

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Solid Tumor, Hematological Malignancy Trial in Beijing (Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other

Recruiting
  • Solid Tumor
  • Hematological Malignancy
  • Metoprolol
  • metoprolol, infliximab, etanercept, tocilizumab and/or other agents
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinese PLA General Hospital
Apr 8, 2022

Hepatocellular Carcinoma Trial in China (CAR-GPC3 T Cells)

Completed
  • Hepatocellular Carcinoma
  • CAR-GPC3 T Cells
  • Guangzhou, Guangdong, China
  • +5 more
Feb 8, 2022

B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma Trial (Autologous Humanized CD19-Directed Chimeric

Not yet recruiting
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)
  • B Lineage Lymphoblastic Lymphoma
  • Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
  • (no location specified)
Jul 27, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Platinum-Resistant Ovarian Carcinoma
  • Chimeric Antigen Receptor T-cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jul 21, 2022

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Non-Hodgkin Lymphoma Trial in Saint Louis, Cleveland (Cyclophosphamide, Fludarabine, CAR-T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Saint Louis, Missouri
  • +1 more
Mar 10, 2022

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Advanced Pancreatic Carcinoma Trial in Shenzhen (CD276 CAR-T cells)

Recruiting
  • Advanced Pancreatic Carcinoma
  • CD276 CAR-T cells
  • Shenzhen, Guangdong, China
    Li Yu
Dec 2, 2021